{
    "body": "What is the effect of ranolazine in diastolic heart failure?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/17027025", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18439620", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24251065", 
        "http://www.ncbi.nlm.nih.gov/pubmed/7873471", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22343711", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19333133", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19403851", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22465693", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21538388", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20924097", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22767404", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23596505", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19752362"
    ], 
    "ideal_answer": [
        "Data from in vitro and animal studies indicate that ranolazine improves diastolic function by inhibiting the late sodium current. Ranolazine is an innovative anti-ischemic and antianginal agent that reduces the Na-dependent Ca-overload, which improves diastolic tone and oxygen handling during myocardial ischemia. Furthermore, ranolazine improves cardiac diastolic dysfunction through modulation of myofilament calcium sensitivity."
    ], 
    "concepts": [
        "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D054144", 
        "http://www.biosemantics.org/jochem#4202863"
    ], 
    "type": "summary", 
    "id": "532f05a5d6d3ac6a34000025", 
    "snippets": [
        {
            "offsetInBeginSection": 253, 
            "offsetInEndSection": 383, 
            "text": "Data from in vitro and animal studies indicate that ranolazine improves diastolic function by inhibiting the late sodium current. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21538388", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 71, 
            "offsetInEndSection": 384, 
            "text": "Ranolazine is an innovative anti-ischemic and antianginal agent that inhibits the late Na current, thereby reducing the Na-dependent Ca-overload, which improves diastolic tone and oxygen handling during myocardial ischemia. In addition, ranolazine seems to exert beneficial effects on diastolic cardiac function. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22767404", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 103, 
            "text": "Ranolazine improves cardiac diastolic dysfunction through modulation of myofilament calcium sensitivity", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22343711", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 1569, 
            "offsetInEndSection": 1799, 
            "text": "Diastolic dysfunction could be reversed by ranolazine, probably resulting from a direct effect on myofilaments, indicating that cardiac oxidative stress may mediate diastolic dysfunction through altering the contractile apparatus.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22343711", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 748, 
            "offsetInEndSection": 981, 
            "text": "Ranolazine (10 microM) significantly reduced the PC-induced increase in LVEDP by 72 +/- 6% (n = 6, p < 0.001), reduced left ventricular wall stiffness, and attenuated the PC-induced increase of CPP by 53 +/- 10% (n = 6-7, p < 0.05). ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19403851", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 685, 
            "offsetInEndSection": 804, 
            "text": " Ranolazine, a specific inhibitor of late INa, reduces Na influx and hence ameliorates disturbed Na and Ca homeostasis.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19333133", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1120, 
            "offsetInEndSection": 1288, 
            "text": "New clinical and experimental studies even point to potential antiarrhythmic effects, beneficial effects in diastolic heart failure, and under hyperglycemic conditions.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19333133", 
            "endSection": "abstract"
        }
    ]
}